AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

BerGenBio

Director's Dealing Sep 2, 2019

3555_dirs_2019-09-02_35d386f4-0af0-451b-8b24-bf37203857f5.html

Director's Dealing

Open in Viewer

Opens in native device viewer

BerGenBio ASA: Primary insider notification

BerGenBio ASA: Primary insider notification

Bergen, Norway, 2 September 2019.

BerGenBio ASA (the"Company") (OSE: BGBIO). Reference is made to the stock

exchange notice dated 28 August 2019 and primary insiders exercise of share

options which expire in 2019.

Primary Insider Richard Godfrey (CEO) exercised 225,000 options equal to 225,000

shares. To cover costs related to the exercise, Richard Godfrey transferred his

rights to receive shares resulting from the exercise of options to a third

party. A total of 177,366 shares were sold at an average price of NOK 13.94 and

Richard Godfrey received the remaining 47,634 shares. Following the transaction,

Richard Godfrey holds 215,449 shares in the Company through Gnist Holding AS and

holds 1,129,284 unexercised options in the Company.

Primary Insider James Lorens (CSO) exercised 150,000 options equal to 150,000

shares. To cover costs related to the exercise, James Lorens transferred his

rights to receive shares resulting from the exercise of options to a third

party. A total of 119,961 shares were sold at an average price of NOK 13.94 and

James Lorens received the remaining 30,039 shares. Following the transaction,

James Lorens holds 280,039 shares in the Company and holds 588,507 unexercised

options in the Company.

Primary Insider Endre Kjærland (Associate Director of IP and Contracts)

exercised 15,000 options equal to 15,000 shares. To cover costs related to the

exercise, Endre Kjærland transferred his rights to receive shares resulting from

the exercise of options to a third party. A total of 13,246 shares were sold at

an average price of 13.94 and Endre Kjærland received the remaining 1,754

shares. Following the transaction, Endre Kjærland holds 3,262 shares in the

Company and holds 88,525 unexercised options in the Company.

-End-

Contacts

Richard Godfrey

CEO, BerGenBio ASA

+47 917 86 304

Rune Skeie

CFO, BerGenBio ASA

[email protected]

+47 917 86 513

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the

expectations expressed or implied in this announcement by such forward-looking

statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

Talk to a Data Expert

Have a question? We'll get back to you promptly.